Literature DB >> 29286561

Intracranial metastasis in fibrolamellar hepatocellular carcinoma.

William J Hammond1,2, Gadi Lalazar2, James A Saltsman1,2, Benjamin A Farber1,2, Enrico Danzer1, Tshering C Sherpa2, Charles D Banda2, Jeffrey R Andolina3, Sasan Karimi4, Cameron W Brennan5,6, Michael S Torbenson7, Michael P La Quaglia1, Sanford M Simon2.   

Abstract

Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare liver malignancy in adolescents and young adults. Surgery is the mainstay of therapy for primary and metastatic disease. Most patients relapse, with development of both local and distant metastases. Brain metastases from solid tumors are rare in the pediatric and young adult population. Here, we document three patients with brain metastases from FLHCC, confirmed by histology and molecular characterization of the chimeric fusion DNAJB1-PRKACA, each necessitating neurosurgical intervention. These observations highlight the ability of FLHCC to metastasize to the brain and suggest the need for surveillance neuroimaging for patients with advanced-stage disease.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  adolescent and young adult tumors; brain; fibrolamellar; liver; rare tumors; tumor biology; tumors

Mesh:

Substances:

Year:  2017        PMID: 29286561      PMCID: PMC6028006          DOI: 10.1002/pbc.26919

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  27 in total

1.  [Fibrolamellar hepatocarcinoma with a long clinical course and possible production of fibrinogen].

Authors:  J Ordi Majá; J L Sarasa Corral; J M Cortés; H Oliva
Journal:  Rev Clin Esp       Date:  1986-10       Impact factor: 1.556

2.  Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma.

Authors:  Ryan T Groeschl; John T Miura; Ray K Wong; Mark Bloomston; Michael L Lidsky; Bryan M Clary; Robert C G Martin; Giulio Belli; Joseph F Buell; T Clark Gamblin
Journal:  J Surg Oncol       Date:  2014-05-21       Impact factor: 3.454

3.  Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma.

Authors:  Ahmed O Kaseb; Mohamed Shama; Ibrahim Halil Sahin; Ajay Nooka; Hesham M Hassabo; Jean-Nicolas Vauthey; Thomas Aloia; James L Abbruzzese; Ishwaria M Subbiah; Filip Janku; Steven Curley; Manal M Hassan
Journal:  Oncology       Date:  2013-09-19       Impact factor: 2.935

4.  DNAJB1-PRKACA is specific for fibrolamellar carcinoma.

Authors:  Rondell P Graham; Long Jin; Darlene L Knutson; Sara M Kloft-Nelson; Patricia T Greipp; Nina Waldburger; Stephanie Roessler; Thomas Longerich; Lewis R Roberts; Andre M Oliveira; Kevin C Halling; Peter Schirmacher; Michael S Torbenson
Journal:  Mod Pathol       Date:  2015-02-20       Impact factor: 7.842

5.  Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

Authors:  Joshua N Honeyman; Elana P Simon; Nicolas Robine; Rachel Chiaroni-Clarke; David G Darcy; Irene Isabel P Lim; Caroline E Gleason; Jennifer M Murphy; Brad R Rosenberg; Lydia Teegan; Constantin N Takacs; Sergio Botero; Rachel Belote; Soren Germer; Anne-Katrin Emde; Vladimir Vacic; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon
Journal:  Science       Date:  2014-02-28       Impact factor: 47.728

6.  Aggressive surgical management of fibrolamellar hepatocellular carcinoma.

Authors:  A W Hemming; B Langer; P Sheiner; P D Greig; B R Taylor
Journal:  J Gastrointest Surg       Date:  1997 Jul-Aug       Impact factor: 3.452

7.  CT and MRI of primary and metastatic fibrolamellar carcinoma: a case series of 37 patients.

Authors:  R K G Do; A McErlean; C S Ang; R P DeMatteo; G K Abou-Alfa
Journal:  Br J Radiol       Date:  2014-06-04       Impact factor: 3.039

8.  Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.

Authors:  Celina S Ang; R Katie Kelley; Michael A Choti; David P Cosgrove; Joanne F Chou; David Klimstra; Michael S Torbenson; Linda Ferrell; Timothy M Pawlik; Yuman Fong; Eileen M O'Reilly; Jennifer Ma; Joseph McGuire; Gandhi P Vallarapu; Ann Griffin; Francesco Stipa; Marinela Capanu; Ronald P Dematteo; Alan P Venook; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2013-01

9.  Is histological diagnosis of primary liver carcinomas with fibrous stroma reproducible among experts?

Authors:  G Malouf; B Falissard; D Azoulay; F Callea; L D Ferrell; Z D Goodman; Y Hayashi; H-C Hsu; S G Hubscher; M Kojiro; I O Ng; A C Paterson; M Reynes; E-S Zafrani; J-F Emile
Journal:  J Clin Pathol       Date:  2009-01-20       Impact factor: 3.411

10.  Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma.

Authors:  Pauline Gras; Stéphanie Truant; Valérie Boige; Laure Ladrat; Philippe Rougier; François-René Pruvot; Mohamed Hebbar
Journal:  Case Rep Oncol       Date:  2012-04-03
View more
  2 in total

Review 1.  A framework for fibrolamellar carcinoma research and clinical trials.

Authors:  Timothy A Dinh; Alan F Utria; Kevin C Barry; Rosanna Ma; Ghassan K Abou-Alfa; John D Gordan; Elizabeth M Jaffee; John D Scott; Jessica Zucman-Rossi; Allison F O'Neill; Mark E Furth; Praveen Sethupathy
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-02-21       Impact factor: 73.082

2.  Predictive value of a nomogram for hepatocellular carcinoma with brain metastasis at initial diagnosis: A population-based study.

Authors:  Qi-Feng Chen; Tao Huang; Lujun Shen; Wang Li
Journal:  PLoS One       Date:  2019-01-02       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.